1.42
Opko Health Inc stock is traded at $1.42, with a volume of 5.23M.
It is up +0.71% in the last 24 hours and up +25.66% over the past month.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
See More
Previous Close:
$1.41
Open:
$1.43
24h Volume:
5.23M
Relative Volume:
2.01
Market Cap:
$1.07B
Revenue:
$581.12M
Net Income/Loss:
$-212.92M
P/E Ratio:
-5.1863
EPS:
-0.2738
Net Cash Flow:
$-174.22M
1W Performance:
-2.07%
1M Performance:
+25.66%
6M Performance:
+8.40%
1Y Performance:
+10.08%
Opko Health Inc Stock (OPK) Company Profile
Name
Opko Health Inc
Sector
Industry
Phone
305-575-4181
Address
4400 BISCAYNE BLVD., MIAMI, FL
Compare OPK vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
OPK
Opko Health Inc
|
1.42 | 1.07B | 581.12M | -212.92M | -174.22M | -0.2738 |
|
TMO
Thermo Fisher Scientific Inc
|
464.61 | 172.66B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
177.17 | 125.40B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
562.09 | 44.34B | 4.45B | 1.10B | 1.06B | 13.59 |
|
A
Agilent Technologies Inc
|
127.06 | 35.89B | 7.23B | 1.41B | 1.09B | 4.979 |
|
WAT
Waters Corp
|
355.44 | 34.90B | 3.77B | 449.25M | 240.68M | 7.8556 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-25 | Initiated | JP Morgan | Neutral |
| Oct-31-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-25-25 | Initiated | JP Morgan | Neutral |
| Jun-29-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Dec-15-22 | Initiated | H.C. Wainwright | Buy |
| Jan-24-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-21-21 | Initiated | Ladenburg Thalmann | Buy |
| Nov-25-19 | Initiated | Piper Jaffray | Overweight |
| Mar-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-14-17 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-21-16 | Reiterated | Standpoint Research | Buy |
| Jun-03-16 | Initiated | Standpoint Research | Buy |
| Mar-31-16 | Reiterated | Barrington Research | Outperform |
| Oct-16-15 | Initiated | JP Morgan | Overweight |
| Sep-11-15 | Downgrade | Jefferies | Buy → Hold |
| Mar-03-15 | Downgrade | Oppenheimer | Outperform → Perform |
| May-12-14 | Reiterated | Oppenheimer | Outperform |
| Mar-14-14 | Initiated | Oppenheimer | Outperform |
| Nov-13-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-30-13 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-22-12 | Initiated | Barrington Research | Outperform |
| Dec-01-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jul-14-11 | Initiated | Ladenburg Thalmann | Buy |
View All
Opko Health Inc Stock (OPK) Latest News
Opko Health shareholders elect board and approve key proposals at annual meeting - Investing.com
OPKO Health (OPK) AGM 2026 Summary - Quartr
OPK: All proposals passed, with robust pipeline progress and $98M remaining for share repurchases - TradingView
OPKO Health Inc (OPK) Valuation: PE, PB & Fair Value Analysis - TradingKey
OPKO Health Inc (OPK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OPKO Health Inc (OPK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OPKO Health Inc (OPK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
OPKO Health Inc (OPK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OPKO Health Inc (OPK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OPKO Health Inc (OPK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OPKO presents preclinical data on acromegaly drug candidate By Investing.com - Investing.com Australia
OPKO presents preclinical data on acromegaly drug candidate - Investing.com
Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026 - OPKO Health, Inc.
OPKO Health (OPK) up 17.1% since last earnings report: Can it continue? - MSN
OPKO Health (OPK) price target increased by 11.18% to 3.86 - MSN
Discover 3 Promising Penny Stocks With Market Caps Over $20M - simplywall.st
Assessing OPKO Health (OPK) Valuation After Expanded Nicoya RAYALDEE Partnership In Greater China - Yahoo Finance
Here's why you should retain OPK stock in your portfolio for now - MSN
How Investors May Respond To OPKO Health (OPK) Boosting Its Nicoya Stake And RAYALDEE Milestones - Yahoo Finance
OPKO Deepens Nicoya Alliance As RAYALDEE China Prospects Draw Focus - Sahm
OPKO Health (OPK) Amends Partnership With Nicoya Therapeutics to Gain Equity Stake - Insider Monkey
OPK Technical Analysis | Trend, Signals & Chart Patterns | OPKO HEALTH INC (NASDAQ:OPK) - ChartMill
OPKO Health (OPK) Jefferies Global Healthcare Conference 2026 Summary - Quartr
OPK Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
OPKO Health Inc stock (US68375N1037): shares trade steady after recent earnings while valuation stay - AD HOC NEWS
OPKO Health (OPK) Up 17.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Here's Why You Should Retain OPK Stock in Your Portfolio for Now - Zacks Investment Research
OPKO Health stock (US68375N1037): earnings update keeps focus on pipeline and Rayaldee outlook - AD HOC NEWS
OPKO Health stock (US68375N1037): Company updates keep the biotech name in focus - AD HOC NEWS
Opko Health, Inc.Common Stock (NQ: OPK - FinancialContent
OPKO Health stock (US68375N1037): Genomics leader with recent subsidiary activity - AD HOC NEWS
ModeX to present preclinical CAR-T data at gene therapy meeting - Investing.com UK
OPKO Health’s ModeX Therapeutics Will Present Data - GlobeNewswire
OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies - Yahoo Finance
Spotlight On Promising Penny Stocks For May 2026 - simplywall.st
OPK.O| Stock Price & Latest News - Reuters
Here's why you should hold OPK stock in your portfolio for now - msn.com
OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
MSN Money - MSN
Opko Health Inc Stock (OPK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Opko Health Inc Stock (OPK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 21 '25 |
Buy |
1.33 |
580,000 |
768,807 |
216,706,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 20 '25 |
Buy |
1.33 |
580,000 |
771,328 |
216,126,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 19 '25 |
Buy |
1.31 |
580,000 |
759,115 |
215,546,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 18 '25 |
Buy |
1.27 |
533,300 |
678,906 |
214,966,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Oct 31 '25 |
Buy |
1.42 |
150,000 |
213,435 |
214,386,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Aug 08 '25 |
Buy |
1.32 |
675,000 |
891,000 |
214,676,448 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):